[1］Simons FE. Mizolastine: antihistaminic activity from preclinical data to clinical evaluation[J].Clin Exp Allergy，1999,29(Suppl 1):3.2 Lebrun-Vignes B, Diquet B, Chosidowo O. Clinical pharmacoki- netics of mizolastine[J] . Clin Pharmacoki net , 2001, 40 (7) : 501. [3］Kontou-Fili K. Clinical advantages of dual activity in urticaria (J).Allergy , 2000 ; 55 (Suppl 64) : 28. [4］Yap YG,Camm AJ.The current cardiac safety situation with an- tihistamines[J].CLireFxp Allergy,1999;29 (Suppl 1):15. [5］Chaufour S, Captain H, Lilienthal N, et al .Study of cardiac repo- lariiation in heapthy volunteers performed with mizolastine, a new H1-receptor antagonist[J].Br J Clin Pharmacol，1999;47(5):515. [6］Eynadier F, Duarte-Risselin C, Murrieta M. Comparative the rapeutic effect and safety of mizolastine and loratadine inchronic iopathic urticaria. URTILOR study group[J].Eur J Diermatol， 2000,10(3):205. [7］Ring J, Brockow K, Ollert M, et al . Antihistamines in urticaria [J].Clin Ezp Allergy , 1999,29( Suppl 1):31. [8］Prakash A, Lamb HM. Miwlastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria(J).Bioelrug, 1998, 10:42.